Healthcare / Diagnostics & ResearchTaipei Exchange
$66.20
-0.50 (-0.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $73.0M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
64.9x
↑EV/EBITDA
38.4x
↑ROE
4.0%
↑Gross Margin
55.3%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.0%
FCF CAGR
-36.4%
FCF margin
1.3%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.24B · net income $51.4M · FCF $15.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.24B | $1.24B | $1.22B | $1.13B | $980.4M |
| Net Income | $51.4M | $51.4M | $83.7M | $78.4M | $38.0M |
| EBITDA | $83.1M | $83.1M | $149.1M | $147.1M | $114.0M |
| EPS | — | — | 1.65 | 1.55 | 0.72 |
| Gross Margin | 55.3% | 55.3% | 56.1% | 56.6% | 55.3% |
| Operating Margin | -1.0% | -1.0% | 5.2% | 7.7% | 6.1% |
| Net Margin | 4.2% | 4.2% | 6.8% | 7.0% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.07 | 0.04 | 0.01 |
| Current Ratio | 4.23 | 4.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.9M | $15.9M | $73.0M | $126.8M | $61.7M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 6.3% | 6.6% | 3.5% |
| Valuation | |||||
| P/E | 64.90 | 64.90 | 48.48 | 33.62 | 53.12 |
| EV/EBITDA | 38.39 | 38.39 | 26.30 | 16.64 | 16.39 |
| P/B | 2.62 | 2.62 | 3.05 | 2.22 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | 1.2% | 1.2% | 8.4% | 15.0% | — |
| EPS Growth | — | — | 6.5% | 115.6% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.6%
Start / end P/E
n/dx → n/dx
EPS bridge
1.65 → n/d
Residual
-8.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.